Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored diabetes education targets individual complication risks

NCT ID NCT07793305

Disease control Sponsor: Taiwanese Association of Diabetes Educators Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether personalized education, guided by a risk assessment for six major diabetes complications, can improve blood sugar control in adults with type 2 diabetes. Participants receive education focused on their highest predicted risk, such as kidney disease or stroke, along with standard care. The study measures changes in hemoglobin A1c over six months to see if this tailored approach helps prevent complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Precision diabetes education, a personalized education program based on individual risk assessment for diabetes complications
What this could lead to
If it works, this could point toward a more effective way to prevent diabetes complications by tailoring education to each person's highest risk.
What could go wrong
This is a relatively small study, and the outcome depends on how well participants follow the education. The benefit may be modest or not generalizable to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

180 people

The number who actually took part.

Started

Mar 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or older with a diagnosis of type 2 diabetes mellitus and without established chronic diabetes complications. 2. Hemoglobin A1c between 7% and 9%. 3. Stable type and dosage of glucose-lowering medications during the preceding 6 months. 4. Ability to independently understand the study information and procedures and to make an informed decision regarding participation. 5. Willingness to provide written informed consent. Exclusion Criteria: 1. Clinically unstable conditions, including acute diabetes-related conditions such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, severe hypoglycemia, acute infection, or acute organ injury. 2. Terminal illness requiring palliative care or other conditions for which active treatment is no longer appropriate. 3. Unwillingness or inability to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetes Complications type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 833401, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 80756, Taiwan

  • MacKay Memorial Hospital

    Taipei, Taipei, 104213, Taiwan

  • National Cheng Kung University Hospital

    Tainan, 704302, Taiwan

  • National Taiwan University Hospital

    Taipei, Taipei, 100225, Taiwan

  • Taichung Veterans General Hospital

    Taichung, 407219, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.